v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
StereoLabs
Common Stock
Common Stock
StereoLabs
Common Stock
Velodyne Merger
Additional Paid-in- Capital
Additional Paid-in- Capital
StereoLabs
Accumulated Deficit
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2024     52,560,770            
Beginning balance at Dec. 31, 2024 $ 180,911   $ 47     $ 1,094,938   $ (913,071) $ (1,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of stock options (in shares)     13,558            
Issuance of common stock upon exercise of stock options 28         28      
Issuance of common stock in connection with Stereolabs acquisition/ Velodyne Merger (in shares)         164,394        
Issuance of common stock upon vesting of restricted stock units (in shares)     1,118,320            
Forfeited restricted stock awards (in shares)     (68,072)            
Common stock warrants issuable to customer 397         397      
Stock-based compensation expense 8,498         8,498      
Net loss (22,017)             (22,017)  
Other comprehensive (loss) income 126               126
Ending balance (in shares) at Mar. 31, 2025     53,788,970            
Ending balance at Mar. 31, 2025 $ 167,943   $ 47     1,103,861   (935,088) (877)
Beginning balance (in shares) at Dec. 31, 2025 60,947,757   60,947,757            
Beginning balance at Dec. 31, 2025 $ 261,738   $ 48     1,235,580   (973,448) (442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of stock options (in shares) 44,548   44,548            
Issuance of common stock upon exercise of stock options $ 94         94      
Issuance of common stock in connection with Stereolabs acquisition/ Velodyne Merger (in shares)       1,847,677          
Issuance of common stock in connection with Stereolabs acquisition   $ 22,779         $ 22,779    
Issuance of common stock upon vesting of restricted stock units (in shares)     621,109            
Common stock warrants issuable to customer 1,101         1,101      
Stock-based compensation expense 7,494         7,494      
Net loss (17,465)             (17,465)  
Other comprehensive (loss) income $ (120)               (120)
Ending balance (in shares) at Mar. 31, 2026 63,461,091   63,461,091            
Ending balance at Mar. 31, 2026 $ 275,621   $ 48     $ 1,267,048   $ (990,913) $ (562)